Lexicon Pharmaceuticals, Inc.
LXRX
$1.12
-$0.03-2.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,652.64% | 11.68% | 3,682.62% | 980.25% | 419.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,652.64% | 11.68% | 3,682.62% | 980.25% | 419.56% |
| Cost of Revenue | -10.41% | -1.29% | 74.84% | 47.17% | -87.32% |
| Gross Profit | 13,843.94% | 30.91% | 104.39% | -38.49% | 98.61% |
| SG&A Expenses | -76.14% | -63.79% | -32.43% | 22.85% | 30.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.91% | -42.02% | 2.16% | 31.43% | 27.93% |
| Operating Income | 106.75% | 43.35% | 54.88% | -28.33% | -25.12% |
| Income Before Tax | 106.09% | 47.73% | 32.14% | -28.28% | -18.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 106.09% | 47.73% | 32.14% | -28.28% | -18.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 106.09% | 47.73% | 32.14% | -28.28% | -18.98% |
| EBIT | 106.75% | 43.35% | 54.88% | -28.33% | -25.12% |
| EBITDA | 107.09% | 43.56% | 55.01% | -28.47% | -25.22% |
| EPS Basic | 105.24% | 64.55% | 54.01% | 13.09% | 21.61% |
| Normalized Basic EPS | 105.21% | 64.56% | 69.91% | 13.03% | 21.61% |
| EPS Diluted | 105.24% | 64.55% | 54.01% | 13.09% | 21.61% |
| Normalized Diluted EPS | 105.21% | 64.56% | 69.91% | 13.03% | 21.61% |
| Average Basic Shares Outstanding | 16.88% | 47.55% | 47.59% | 47.59% | 51.79% |
| Average Diluted Shares Outstanding | 16.97% | 47.55% | 47.59% | 47.59% | 51.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |